| Angioedemas, Hereditary
Sajazir vs Cinryze
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Sajazir vs Cinryze with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCinryze has a higher rate of injection site reactions vs Sajazir based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cinryze but not Sajazir, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sajazir
Cinryze
At A Glance
SC injection
As needed
Bradykinin B2 receptor antagonist
IV infusion
Every 3-4 days
C1 esterase inhibitor (serpin)
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 30 mg SC injection in the abdominal area; additional doses at intervals of at least 6 hours if response is inadequate or symptoms recur; no more than 3 doses in 24 hours.
Angioedemas, Hereditary (adults and adolescents 12 years and above) 1,000 IU IV every 3 or 4 days at 1 mL/min (10 min); for inadequate responders, doses up to 2,000 IU (not exceeding 80 IU/kg) every 3 or 4 days may be considered.
Angioedemas, Hereditary (pediatric patients 6-11 years) 500 IU IV every 3 or 4 days at 1 mL/min (5 min); dose may be adjusted up to 1,000 IU every 3 or 4 days based on individual response.
Contraindications
—
- Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to CINRYZE or any of its excipients
Adverse Reactions
Most common (>1%) Injection site reactions, pyrexia, transaminase increased, dizziness
Postmarketing Urticaria
Most common (>=5%) Headache, nausea, rash, vomiting, fever
Serious Cerebrovascular accident
Postmarketing Local infusion site reactions (inflammation or hematoma at infusion site), hypersensitivity
Pharmacology
Icatibant is a competitive antagonist selective for the bradykinin B2 receptor; by blocking bradykinin binding to the B2 receptor, it treats the localized swelling, inflammation, and pain of acute HAE attacks caused by C1-esterase-inhibitor deficiency-driven excess bradykinin production.
C1 esterase inhibitor (serpin) that regulates complement and intrinsic coagulation (contact system) pathway activation; suppresses contact system activation by inactivating plasma kallikrein and factor XIIa, modulating vascular permeability by preventing bradykinin generation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sajazir
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Cinryze
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Sajazir
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Cinryze
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Sajazir
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Cinryze
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SajazirView full Sajazir profile
CinryzeView full Cinryze profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.